Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953019 | 1.00 | CSNK2A1 (0.44) | CSNK2A1ENPP2FABP4ALDH1A1MEN1 | |
| SCHEMBL29956963 | 0.92 | ENPP2 (0.43) | ENPP2ALDH1A1MEN1USP2POLB | |
| SCHEMBL182934 | 0.87 | ENPP2 (0.57) | CSNK2A1ENPP2ALDH1A1MEN1USP2 | |
| SCHEMBL29956646 | 0.86 | ENPP2 (0.46) | ENPP2ALDH1A1POLBMAPTHPGD | |
| SCHEMBL2854999 | 0.86 | ENPP2 (0.46) | ENPP2ALDH1A1POLBMAPTHPGD | |
| SCHEMBL2561475 | 0.85 | L3MBTL1 (0.46) | ENPP2ALDH1A1MEN1USP2POLB | |
| SCHEMBL3791885 | 0.84 | MAPT (0.47) | CSNK2A1ENPP2ALDH1A1MEN1USP2 | |
| SCHEMBL2551648 | 0.83 | UTS2R (0.46) | ENPP2ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL31469079 | 0.82 | ALDH1A1 (0.50) | ENPP2ALDH1A1MEN1USP2POLB | |
| SCHEMBL7420999 | 0.80 | HSD17B10 (0.44) | ENPP2ALDH1A1MEN1USP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| CN-112279808-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112250627-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-27 | — | — | US | disclosed |
| US-11426407-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-08-30 | — | — | US | disclosed |
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-02-25 | — | — | US | disclosed |
| CN-112250627-A | Cystic fibrosis transmembrane transduction modulator modulators | 弗特克斯药品有限公司 | 2021-01-22 | — | — | CN | disclosed |
| CN-107690281-B | Cystic fibrosis transmembrane transduction modulator modulators | 弗特克斯药品有限公司 | 2020-11-17 | — | — | CN | disclosed |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-09-01 | — | — | US | disclosed |
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-05 | — | — | US | disclosed |
| US-9782408-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-10 | — | — | US | disclosed |
| EP-3203840-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| WO-2016057572-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | MILLER MARK THOMAS (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160095858-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-04-07 | — | — | US | disclosed |
| US-20080293939-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS ANTI-HYPERALGESIC AGENTS | CULSHAW ANDREW JAMES | 2008-11-27 | — | — | US | disclosed |
| US-20060154942-A1 | Quinazolinone derivatives useful as anti-hyperalgesic agents | CULSHAW ANDREW J | 2006-07-13 | — | — | US | disclosed |
| EP-1554257-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS ANTI-HYPERALGESIC AGENTS | Novartis AG (CH) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004033435-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS ANTI-HYPERALGESIC AGENTS | NOVARTIS AG (CH) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293939-A1 | QUINAZOLINONE DERIVATIVES USEFUL AS ANTI-HYPERALGESIC AGENTS | OPRK1, OPRL1, TRPV1 | CSNK2A1 413/4885ENPP2 993/4885FABP4 3052/4885 |
| US-11426407-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | CSNK2A1 2068/4885ENPP2 520/4885FABP4 4301/4885 |
| US-20180185364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CSNK2A1 2068/4885ENPP2 520/4885FABP4 4301/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CSNK2A1 2068/4885ENPP2 520/4885FABP4 4301/4885 |
| US-20210052584-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CSNK2A1 2068/4885ENPP2 520/4885FABP4 4301/4885 |
| US-20230233560-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CSNK2A1 2068/4885ENPP2 520/4885FABP4 4301/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | CSNK2A1 2068/4885ENPP2 520/4885FABP4 4301/4885 |
| US-20060154942-A1 | Quinazolinone derivatives useful as anti-hyperalgesic agents | OPRK1, OPRL1, TRPV1 | CSNK2A1 413/4885ENPP2 993/4885FABP4 3052/4885 |
| US-20160095858-A1 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator | CFTR, SCNN1B, SLC26A4 | CSNK2A1 2068/4885ENPP2 520/4885FABP4 4301/4885 |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | CSNK2A1 2068/4885ENPP2 520/4885FABP4 4301/4885 |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | CSNK2A1 2068/4885ENPP2 520/4885FABP4 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.